{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T18:03:31Z","timestamp":1791914611571,"version":"4.3.4"},"reference-count":103,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100001006","name":"Breast Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004634","name":"Mount Sylvia Diatomite","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004634","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001026","name":"National Breast Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Cancer"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.trecan.2024.02.008","type":"journal-article","created":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T14:41:59Z","timestamp":1711118519000},"page":"490-506","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["The anti-cancer immune response in breast cancer: current and emerging biomarkers and treatments"],"prefix":"10.1016","volume":"10","author":[{"given":"Victoria C.","family":"Rayson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Savas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L.","family":"Hun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balaji","family":"Virassamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Salgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6137-9171","authenticated-orcid":false,"given":"Sherene","family":"Loi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trecan.2024.02.008_bb0005","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1200\/JCO.2011.41.0902","article-title":"Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98","volume":"31","author":"Loi","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2024.02.008_bb0010","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/annonc\/mdu450","article-title":"The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014","volume":"26","author":"Salgado","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2024.02.008_bb0015","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1200\/JCO.18.01010","article-title":"Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers","volume":"37","author":"Loi","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2024.02.008_bb0020","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41523-021-00362-1","article-title":"Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer","volume":"8","author":"Loi","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.trecan.2024.02.008_bb0025","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S1470-2045(17)30904-X","article-title":"Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy","volume":"19","author":"Denkert","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.trecan.2024.02.008_bb0030","article-title":"Association between biomarkers and clinical outcomes of pembrolizumab monotherapy in patients with metastatic triple-negative breast cancer: KEYNOTE-086 exploratory analysis","volume":"7","author":"Loi","year":"2023","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.trecan.2024.02.008_bb0035","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/annonc\/mdz235","article-title":"Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019","volume":"30","author":"Burstein","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2024.02.008_bb0040","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/annonc\/mdz173","article-title":"Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Cardoso","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2024.02.008_bb0045","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/s41523-021-00346-1","article-title":"The tale of TILs in breast cancer: a report from the International Immuno-Oncology Biomarker Working Group","volume":"7","author":"El Bairi","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.trecan.2024.02.008_bb0050","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1073\/pnas.1104303108","article-title":"Leukocyte composition of human breast cancer","volume":"109","author":"Ruffell","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.trecan.2024.02.008_bb0055","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1038\/s41591-018-0078-7","article-title":"Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis","volume":"24","author":"Savas","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.trecan.2024.02.008_bb0060","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.cell.2018.05.060","article-title":"Single-cell map of diverse immune phenotypes in the breast tumor microenvironment","volume":"174","author":"Azizi","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.trecan.2024.02.008_bb0065","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2020107333","article-title":"A single-cell RNA expression atlas of normal, preneoplastic and tumorigenic states in the human breast","volume":"40","author":"Pal","year":"2021","journal-title":"EMBO J."},{"key":"10.1016\/j.trecan.2024.02.008_bb0070","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1038\/s41588-021-00911-1","article-title":"A single-cell and spatially resolved atlas of human breast cancers","volume":"53","author":"Wu","year":"2021","journal-title":"Nat. Genet."},{"key":"10.1016\/j.trecan.2024.02.008_bb0075","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.immuni.2016.10.032","article-title":"Regulatory T cells exhibit distinct features in human breast cancer","volume":"45","author":"Plitas","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.trecan.2024.02.008_bb0080","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1158\/1078-0432.CCR-17-2257","article-title":"CD103+ tumor-resident CD8+ T cells are associated with improved survival in immunotherapy-na\u00efve melanoma patients and expand significantly during anti-PD-1 treatment","volume":"24","author":"Edwards","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2024.02.008_bb0085","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/ni.3775","article-title":"Tissue-resident memory features are linked to the magnitude of cytotoxic T cell responses in human lung cancer","volume":"18","author":"Ganesan","year":"2018","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.trecan.2024.02.008_bb0090","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.ccell.2023.01.004","article-title":"Intratumoral CD8+ T cells with a tissue-resident memory phenotype mediate local immunity and immune checkpoint responses in breast cancer","volume":"41","author":"Virassamy","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.trecan.2024.02.008_bb0095","doi-asserted-by":"crossref","first-page":"5668","DOI":"10.1038\/s41467-021-25962-0","article-title":"Spatial immunophenotypes predict response to anti-PD1 treatment and capture distinct paths of T cell evasion in triple negative breast cancer","volume":"12","author":"Hammerl","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2024.02.008_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.anndiagpath.2020.151676","article-title":"Clinicopathological significance of the immunologic signature (PDL1, FOXP3+ Tregs, TILs) in early stage triple-negative breast cancer treated with neoadjuvant chemotherapy","volume":"51","author":"Abdelrahman","year":"2021","journal-title":"Ann. Diagn. Pathol."},{"key":"10.1016\/j.trecan.2024.02.008_bb0105","doi-asserted-by":"crossref","first-page":"4290","DOI":"10.1158\/0008-5472.CAN-20-3773","article-title":"Tumor-infiltrating B lymphocyte profiling identifies IgG-biased, clonally expanded prognostic phenotypes in triple-negative breast cancer","volume":"81","author":"Harris","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2024.02.008_bb0110","article-title":"Tumor infiltrating B-cells signal functional humoral immune responses in breast cancer","volume":"5","author":"Garaud","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.trecan.2024.02.008_bb0115","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1172\/JCI67428","article-title":"CD4+ follicular helper T cell infiltration predicts breast cancer survival","volume":"123","author":"Gu-Trantien","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.trecan.2024.02.008_bb0120","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","article-title":"B cells and tertiary lymphoid structures promote immunotherapy response","volume":"577","author":"Helmink","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2024.02.008_bb0125","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41577-019-0127-6","article-title":"Macrophages as regulators of tumour immunity and immunotherapy","volume":"19","author":"DeNardo","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.trecan.2024.02.008_bb0130","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.cell.2019.03.005","article-title":"A single-cell atlas of the tumor and immune ecosystem of human breast cancer","volume":"177","author":"Wagner","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.trecan.2024.02.008_bb0135","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.ccell.2014.09.007","article-title":"Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity","volume":"26","author":"Broz","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.trecan.2024.02.008_bb0140","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1126\/science.1164206","article-title":"Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity","volume":"322","author":"Hildner","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.trecan.2024.02.008_bb0145","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aav3942","article-title":"IFN-III is selectively produced by cDC1 and predicts good clinical outcome in breast cancer","author":"Hubert","year":"2020","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.trecan.2024.02.008_bb0150","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nature16140","article-title":"Neutrophils support lung colonization of metastasis-initiating breast cancer cells","volume":"528","author":"Wculek","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2024.02.008_bb0155","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1093\/annonc\/mdy547","article-title":"Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy","volume":"30","author":"Luen","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2024.02.008_bb0160","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.annonc.2022.07.1940","article-title":"Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response","volume":"33","author":"Loibl","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2024.02.008_bb0165","doi-asserted-by":"crossref","first-page":"S1260","DOI":"10.1016\/j.annonc.2023.10.011","article-title":"LBA21 KEYNOTE-756: Phase III study of neoadjuvant pembrolizumab (pembro) or placebo (pbo) + chemotherapy (chemo), followed by adjuvant pembro or pbo + endocrine therapy (ET) for early-stage high-risk ER+\/HER2- breast cancer","volume":"34","author":"Cardoso","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2024.02.008_bb0170","doi-asserted-by":"crossref","first-page":"S1259","DOI":"10.1016\/j.annonc.2023.10.010","article-title":"LBA20 A randomized, double-blind trial of nivolumab (NIVO) vs placebo (PBO) with neoadjuvant chemotherapy (NACT) followed by adjuvant endocrine therapy (ET) +\/-; NIVO in patients (pts) with high-risk, ER+ HER2-; primary breast cancer (BC)","volume":"34","author":"Loi","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2024.02.008_bb0175","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1200\/JCO.2023.41.16_suppl.1009","article-title":"Characterization of the immune microenvironment in matched primary and metastatic breast cancer lesions from the AURORA study: BIG 14-01","volume":"41","author":"Venet","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2024.02.008_bb0180","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1200\/JCO.2023.41.16_suppl.1010","article-title":"Association of tumor infiltrating lymphocyte quantity with survival in patients (pts) with metastatic breast cancer (MBC) receiving microtubule-targeting agents: Post hoc analysis CALGB 40502 (Alliance)","volume":"41","author":"Stover","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2024.02.008_bb0185","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdx440.005","article-title":"Relationship between tumor infiltrating lymphocyte (TIL) levels and response to pembrolizumab (pembro) in metastatic triple-negative breast cancer (mTNBC): Results from KEYNOTE-086","volume":"28","author":"Loi","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2024.02.008_bb0190","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS19-PD5-03","article-title":"Abstract PD5-03: Relationship between tumor-infiltrating lymphocytes (TILs) and outcomes in the KEYNOTE-119 study of pembrolizumab vs chemotherapy for previously treated metastatic triple-negative breast cancer (mTNBC)","volume":"80","author":"Loi","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2024.02.008_bb0195","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.humpath.2015.09.003","article-title":"PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas","volume":"47","author":"Cimino-Mathews","year":"2016","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.trecan.2024.02.008_bb0200","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1257452","article-title":"Tumor-infiltrating lymphocyte composition, organization and PD-1\/ PD-L1 expression are linked in breast cancer","volume":"6","author":"Buisseret","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.trecan.2024.02.008_bb0205","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2024.02.008_bb0210","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial","volume":"396","author":"Cortes","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.trecan.2024.02.008_bb0215","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(20)31953-X","article-title":"Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial","volume":"396","author":"Mittendorf","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.trecan.2024.02.008_bb0220","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/j.annonc.2021.07.007","article-title":"The journey of tumor-infiltrating lymphocytes as a biomarker in breast cancer: clinical utility in an era of checkpoint inhibition","volume":"32","author":"Loi","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2024.02.008_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102257","article-title":"Discordance of PD-L1 status between primary and metastatic breast cancer: A systematic review and meta-analysis","volume":"99","author":"Boman","year":"2021","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.trecan.2024.02.008_bb0230","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1093\/jnci\/djab004","article-title":"Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study","volume":"113","author":"Emens","year":"2021","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"10.1016\/j.trecan.2024.02.008_bb0235","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/annonc\/mdy517","article-title":"Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study","volume":"30","author":"Adams","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2024.02.008_bb0240","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-51537-7","article-title":"Drug-induced PD-L1 expression and cell stress response in breast cancer cells can be balanced by drug combination","volume":"9","author":"Gilad","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.trecan.2024.02.008_bb0245","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/s41379-021-00884-w","article-title":"Quantitative comparison of PD-L1 IHC assays against NIST standard reference material 1934","volume":"35","author":"Sompuram","year":"2022","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.trecan.2024.02.008_bb0250","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S1470-2045(20)30754-3","article-title":"Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial","volume":"22","author":"Winer","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.trecan.2024.02.008_bb0255","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer","volume":"387","author":"Cortes","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2024.02.008_bb0260","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.annonc.2021.05.355","article-title":"First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis","volume":"32","author":"Emens","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2024.02.008_bb0265","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1158\/2159-8290.CD-16-0577","article-title":"Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease","volume":"6","author":"Liu","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.trecan.2024.02.008_bb0270","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMoa2211437","article-title":"Neoadjuvant\u2013Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma","volume":"388","author":"Patel","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2024.02.008_bb0275","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1470-2045(21)00589-1","article-title":"Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients","volume":"23","author":"Yau","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.trecan.2024.02.008_bb0280","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1001\/jamaoncol.2021.3690","article-title":"Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial","volume":"7","author":"Symmans","year":"2021","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.trecan.2024.02.008_bb0285","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1200\/JCO.2022.40.16_suppl.513","article-title":"Clinical and biomarker results of neoadjuvant phase II study of pembrolizumab and carboplatin plus docetaxel in triple-negative breast cancer (TNBC) (NeoPACT)","volume":"40","author":"Sharma","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2024.02.008_bb0290","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.annonc.2020.01.072","article-title":"Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study","volume":"31","author":"Schmid","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2024.02.008_bb0295","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1200\/JCO.2022.40.16_suppl.503","article-title":"Event-free survival by residual cancer burden after neoadjuvant pembrolizumab + chemotherapy versus placebo + chemotherapy for early TNBC: Exploratory analysis from KEYNOTE-522","volume":"40","author":"Pusztai","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2024.02.008_bb0300","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJMoa2112651","article-title":"Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer","volume":"386","author":"Schmid","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2024.02.008_bb0305","series-title":"San Antonio Breast Cancer Symposium","article-title":"(LBO1-01) Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for early-stage triple-negative breast cancer: updated event-free survival results from the phase 3 KEYNOTE-522 study","volume":"2023","author":"Schmid","year":"2023"},{"key":"10.1016\/j.trecan.2024.02.008_bb0310","volume":"8","author":"Barrios","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2024.02.008_bb0315","doi-asserted-by":"crossref","unstructured":"Loi, S. et al. (LBO1-03) Randomized Phase II Study of Neoadjuvant Nivolumab (N) 2 week lead-in followed by 12 weeks of concurrent N+carboplatin plus paclitaxel (CbP) vs concurrent N+CbP in Triple Negative Breast Cancer (TNBC): (BCT1902\/IBCSG 61-20 Neo-N). Presented at 2023 San Antonio Breast Cancer Symposium. San Antonio, Texas.","DOI":"10.1158\/1538-7445.SABCS23-LBO1-03"},{"key":"10.1016\/j.trecan.2024.02.008_bb0320","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/s41523-022-00500-3","article-title":"A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013","volume":"8","author":"Ademuyiwa","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.trecan.2024.02.008_bb0325","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/annonc\/mdz158","article-title":"A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study","volume":"30","author":"Loibl","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2024.02.008_bb0330","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1200\/JCO.21.02772","article-title":"Atezolizumab With Neoadjuvant Anti\u2013Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2\u2013Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial","volume":"40","author":"Huober","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2024.02.008_bb0335","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS22-PD11-03","article-title":"Comparison of an Atezolizumab monotherapy window followed by Atezolizumab and chemotherapy vs. Atezolizumab and chemotherapy alone in triple negative breast cancer (TNBC) \u2013 final analysis of the neoadjuvant neoMono trial","volume":"83","author":"Kolberg","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2024.02.008_bb0340","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41591-019-0432-4","article-title":"Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial","volume":"25","author":"Voorwerk","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.trecan.2024.02.008_bb0345","doi-asserted-by":"crossref","first-page":"6175","DOI":"10.1038\/s41467-020-19933-0","article-title":"Chemotherapy induces dynamic immune responses in breast cancers that impact treatment outcome","volume":"11","author":"Park","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2024.02.008_bb0350","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for Early Triple-Negative Breast Cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2024.02.008_bb0355","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.annonc.2022.01.009","article-title":"Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial","volume":"33","author":"Geyer","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2024.02.008_bb0360","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/s41416-022-02050-8","article-title":"Incorporating weekly carboplatin in anthracycline and paclitaxel-containing neoadjuvant chemotherapy for triple-negative breast cancer: propensity-score matching analysis and TIL evaluation","volume":"128","author":"Dieci","year":"2023","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.trecan.2024.02.008_bb0365","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1001\/jamaoncol.2018.1701","article-title":"Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors","volume":"4","author":"Goodman","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.trecan.2024.02.008_bb0370","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/s41591-020-01189-2","article-title":"Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial","volume":"27","author":"Bachelot","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.trecan.2024.02.008_bb0375","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor mutational load predicts survival after immunotherapy across multiple cancer types","volume":"51","author":"Samstein","year":"2019","journal-title":"Nat. Genet."},{"key":"10.1016\/j.trecan.2024.02.008_bb0380","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.trecan.2024.02.008_bb0385","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.annonc.2019.11.010","article-title":"Prevalence and mutational determinants of high tumor mutation burden in breast cancer","volume":"31","author":"Barroso-Sousa","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2024.02.008_bb0390","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1200\/JCO.2020.38.15_suppl.1013","article-title":"Association of tumor mutational burden (TMB) and clinical outcomes with pembrolizumab (pembro) versus chemotherapy (chemo) in patients with metastatic triple-negative breast cancer (mTNBC) from KEYNOTE-119","volume":"38","author":"Winer","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2024.02.008_bb0395","doi-asserted-by":"crossref","first-page":"S360","DOI":"10.1016\/j.annonc.2020.08.398","article-title":"296P Tumour mutational burden and clinical outcomes with first-line atezolizumab and nab-paclitaxel in triple-negative breast cancer: exploratory analysis of the phase III IMpassion130 trial","volume":"31","author":"Emens","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2024.02.008_bb0400","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.annonc.2020.05.015","article-title":"Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo","volume":"31","author":"Karn","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2024.02.008_bb0405","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.annonc.2022.05.519","article-title":"Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study","volume":"33","author":"Maio","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2024.02.008_bb0410","doi-asserted-by":"crossref","first-page":"5299","DOI":"10.1158\/1078-0432.CCR-21-0607","article-title":"Tumor-Specific Major Histocompatibility-II Expression Predicts Benefit to Anti\u2013PD-1\/L1 Therapy in Patients With HER2-Negative Primary Breast Cancer","volume":"27","author":"Gonzalez-Ericsson","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2024.02.008_bb0415","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1038\/s41467-021-24343-x","article-title":"The T cell receptor repertoire of tumor infiltrating T cells is predictive and prognostic for cancer survival","volume":"12","author":"Valpione","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2024.02.008_bb0420","doi-asserted-by":"crossref","first-page":"5365","DOI":"10.1158\/1078-0432.CCR-21-0144","article-title":"Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer","volume":"27","author":"Yam","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2024.02.008_bb0425","article-title":"Circulating T-Cell Repertoires Correlate With the Tumor Response in Patients With Breast Cancer Receiving Neoadjuvant Chemotherapy","volume":"6","author":"Cai","year":"2022","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.trecan.2024.02.008_bb0430","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2024.02.008_bb0435","article-title":"Abstract PD11-08: PD11-08 Trastuzumab deruxtecan (T-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced\/metastatic hormone receptor-negative (HR\u2212), HER2-low breast cancer: updated results from BEGONIA, a phase 1b\/2 study","volume":"83","author":"Schmid","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2024.02.008_bb0440","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1016\/j.celrep.2018.02.053","article-title":"The CDK4\/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade","volume":"22","author":"Schaer","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.trecan.2024.02.008_bb0445","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14143361","article-title":"CDK Inhibition Primes for Anti-PD-L1 Treatment in Triple-Negative Breast Cancer Models","volume":"14","author":"Cheung","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.trecan.2024.02.008_bb0450","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nature23465","article-title":"CDK4\/6 inhibition triggers anti-tumour immunity","volume":"548","author":"Goel","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2024.02.008_bb0455","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nature25015","article-title":"Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance","volume":"553","author":"Zhang","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2024.02.008_bb0460","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41523-022-00482-2","article-title":"Abemaciclib in combination with pembrolizumab for HR+, HER2- metastatic breast cancer: Phase 1b study","volume":"8","author":"Rugo","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.trecan.2024.02.008_bb0465","doi-asserted-by":"crossref","DOI":"10.1038\/s43018-023-00586-z","article-title":"The expanding success of T cell-engaging bispecific antibodies","author":"Bargou","year":"2023","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.trecan.2024.02.008_bb0470","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2023.101053","article-title":"Tissue-resident memory CAR T cells with stem-like characteristics display enhanced efficacy against solid and liquid tumors","author":"Jung","year":"2023","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.trecan.2024.02.008_bb0475","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1200\/JCO.21.02170","article-title":"Breast Cancers Are Immunogenic: Immunologic Analyses and a Phase II Pilot Clinical Trial Using Mutation-Reactive Autologous Lymphocytes","volume":"40","author":"Zacharakis","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2024.02.008_bb0480","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1200\/JCO.22.00284","article-title":"Challenges of Creating New Tumor-Infiltrating Lymphocyte for Combating Breast Cancer","volume":"40","author":"Beavis","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2024.02.008_bb0485","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/s41577-018-0014-6","article-title":"Integrating oncolytic viruses in combination cancer immunotherapy","volume":"18","author":"Bommareddy","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.trecan.2024.02.008_bb0490","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1200\/JCO.2023.41.16_suppl.1012","article-title":"BRACELET-1 (PrE0113): Inducing an inflammatory phenotype in metastatic HR+\/HER2- breast cancer with the oncolytic reovirus pelareorep in combination with paclitaxel and avelumab","volume":"41","author":"Zhao","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2024.02.008_bb0495","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1200\/JCO.2021.39.15_suppl.1079","article-title":"A phase II trial of stereotactic radiation therapy and in situ oncolytic virus therapy in metastatic triple-negative breast cancer (mTNBC) patients followed by pembrolizumab (STOMP)","volume":"39","author":"Sun","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2024.02.008_bb0500","doi-asserted-by":"crossref","first-page":"CT001","DOI":"10.1158\/1538-7445.AM2023-CT001","article-title":"Abstract CT001: A personalized cancer vaccine, mRNA-4157, combined with pembrolizumab versus pembrolizumab in patients with resected high-risk melanoma: Efficacy and safety results from the randomized, open-label Phase 2 mRNA-4157-P201\/Keynote-942 trial","volume":"83","author":"Khattak","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2024.02.008_bb0505","article-title":"Breast Cancer Vaccines: Disappointing or Promising?","volume":"13","author":"Zhu","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.trecan.2024.02.008_bb0510","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s10549-021-06459-2","article-title":"Breast cancer vaccines for treatment and prevention","volume":"191","author":"Disis","year":"2022","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.trecan.2024.02.008_bb0515","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1001\/jamaoncol.2023.5033","article-title":"Clinical and Biomarker Findings of Neoadjuvant Pembrolizumab and Carboplatin Plus Docetaxel in Triple-Negative Breast Cancer: NeoPACT Phase 2 Clinical Trial","volume":"10","author":"Sharma","year":"2023","journal-title":"JAMA Oncol."}],"container-title":["Trends in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405803324000451?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405803324000451?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T01:21:19Z","timestamp":1718155279000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405803324000451"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":103,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S2405803324000451"],"URL":"https:\/\/doi.org\/10.1016\/j.trecan.2024.02.008","relation":{},"ISSN":["2405-8033"],"issn-type":[{"value":"2405-8033","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The anti-cancer immune response in breast cancer: current and emerging biomarkers and treatments","name":"articletitle","label":"Article Title"},{"value":"Trends in Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trecan.2024.02.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2024 Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}